Skip to search formSkip to main content
You are currently offline. Some features of the site may not work correctly.

gp96-Ig fusion protein-expressing non-small cell lung cancer cell vaccine

Known as: gp96-Ig fusion protein vaccine, HS110, Viagenpumatucel-L 
A proprietary, allogeneic tumor cell vaccine expressing a recombinant secretory form of the heat shock protein gp96 fusion (gp96-Ig) with potential… Expand
National Institutes of Health

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2019
2019
9109Background: Viagenpumatucel-L (HS-110) is an allogeneic cellular vaccine derived from a human lung adenocarcinoma cell line… Expand
Is this relevant?
2019
2019
  • Vikas Tahiliani, Jayalakshmi Miriyala, +4 authors Matthew M. Seavey
  • 2019
  • Corpus ID: 219270435
Our technology is focused on developing a next generation cellular vaccine platform – referred to as ComPACT (COMbination Pan… Expand
Is this relevant?
2019
2019
101Background: Viagenpumatucel-L (HS-110) is an allogeneic cellular vaccine derived from a human lung adenocarcinoma (AD) cell… Expand
Is this relevant?
2016
2016
TPS9102Background: Viagenpumatucel-L (HS-110) is an allogeneic whole-cell vaccine, selected for high expression of adenocarcinoma… Expand
Is this relevant?
2016
2016
 
Is this relevant?
2015
2015
2015
3077 Background: Viagenpumatucel-L (HS-110), consists of an allogeneic NSCLC cell line, selected for high expression of a series… Expand
Is this relevant?
2014
2014
Background Viagenpumatucel-L (HS-110) is an allogeneic cell-based therapeutic cancer vaccine for the treatment of advanced NSCLC… Expand
Is this relevant?
2007
2007
High-level transcription of the globin genes requires the enhancement by a distant element, the locus control region (LCR). Such… Expand
Is this relevant?
Highly Cited
2000
Highly Cited
2000
A major quantitative trait locus (QTL) controlling response to photoperiod, Hd1, was identified by means of a map-based cloning… Expand
  • figure 1
  • figure 2
  • figure 3
  • figure 4
  • figure 5
Is this relevant?